+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of an equilibrium immunoassay using electrochemiluminescent detection for a novel recombinant protein product and its application to pre-clinical product development



Development of an equilibrium immunoassay using electrochemiluminescent detection for a novel recombinant protein product and its application to pre-clinical product development



Journal Of Pharmaceutical & Biomedical Analysis. 16(4): 605-612,.



In order for a biotechnology derived protein product to be considered 'well characterized', a thorough understanding of the pharmacokinetic and metabolic fate of the product is essential. Specifications for such products need to be based on historical data obtained in the pre-clinical, clinical and manufacturing experience through the use of specific, accurate, precise and validated assays. Typically, assays such as ELISA or RIA that have the disadvantages of limited dynamic range, matrix interactions and hazardous waste generation are used to gather this data. We present data in this abstract that demonstrates the utility of an equilibrium immunoassay that uses electrochemiluminescent detection in the assessment of the pharmacokinetic and metabolic fate of a biotechnology derived product based on either the human (AMG1h) or murine (AMG1m) protein sequence. The assay uses biotinylated antibody in a sandwich format with antibody labeled with the N-hydroxysuccinimide ester of a ruthenium (II) tris-bipyridine chelate for detection in the OrigenTM System. Streptavidin-coated paramagnetic beads are used to capture the antibody-antigen-antibody sandwich complex and facilitate electrochemiluminescent detection. The assay standard curve for AMG1h ranges from a lower limit of quantitation (LOQ) of 2.5 ng ml-1 to an upper limit of quantitation (ULQ) of 2000 ng ml-1 with accuracy and precision of not greater then 15% CV and deviation from nominal over the range. The corresponding LOQ (0.5 ng ml-1) and ULQ (200 ng ml-1) values determined for AMG1m displayed similar accuracy and precision. In addition, we demonstrate that the assay as performed is insensitive to matrix effect up to addition of 7% of the total reaction volume. General guidelines for developing similar electrochemiluminescent based assays and their applications, advantages and limitations will be discussed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008453048

Download citation: RISBibTeXText

DOI: 10.1016/s0731-7085(97)00218-5


Related references

Development of an equilibrium immunoassay using electrochemiluminescent detection for a novel recombinant protein product and its application to pre-clinical product development. Journal of Pharmaceutical and Biomedical Analysis 16(4): 605-612, 1998

Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Recombinant Human FSH Product Development Group. Human Reproduction Update 4(6): 862-881, 1999

Development of an Immunoassay for Detection of Torque Teno Virus (TTV) Antibodies Using the N22 Expression Product from TTV Genotype 2. Intervirology 60(5): 207-216, 2018

Challenges in Product Strategy, Product Planning and Technology Development for Product Life Cycle Design. Cirp Annals - Manufacturing Technology 43(1): 157-162, 1994

Product Development In Aquaculture: Deducing Product Form From Product Class Information. Aquaculture Economics & Management 13(3): 213-221, 2009

Sa1268 Clinical Development of an Electrochemiluminescent Immunoassay to Measure Antibodies-to-Infliximab. Gastroenterology 146(5): S-248, 2014

Consumers, customers, marketplaces and markets in New Product Development - a roadmap through marketing and launching in product development. 2008

Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition. Aaps Journal 18(1): 281-285, 2016

Product development in the Finnish mechanized forest industry. Part 1. How to succeed in product development. Tutkimuksia Valtion Teknillinen Tutkimuskeskus ( 394): 110 pp., 1986

Trust in ICT-based new product development - guidelines for virtual new product development teams. Trust and risk in business networks: Proceedings of the 99th Seminar of the European Association of Agricultural Economists EAAE, Bonn, Germany, 8-10 February, 2006: 27-36, 2006

Development of a multi-product leached protein A assay for bioprocess samples containing recombinant human monoclonal antibodies. Journal of Immunological Methods 366(1-2): 20-27, 2011

Opportunity identification in new product development and innovation in food product development. Consumer led food product development: 321-341, 2007

Product development and IP strategies for global health product development partnerships. 2007

Effective education for product development - building New Product Development courses. 2008

Development of a novel multiplex electrochemiluminescent-based immunoassay to aid enterotoxigenic Escherichia coli vaccine development and evaluations. Journal of Immunological Methods 2019, 2019